That's a tough buy in. I was in at a good price but topped up during the results mania too. It's been all downhill since then. Who could have foreseen MT's departure? However, the essence of the investment hasn't changed. An effective global treatment for MND/ALS is possible. With regulatory approval particularly by the FDA, it's worth at least $6 a share. What are the chances of approval? Probably between 20-60%, yet investors may get a 30 bagger. Doesn't mean it's gonna happen but it does look attractive from a risk weighted perspective.
Ann: Board Changes, page-170
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.010(4.88%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.8¢ | $238.9K | 1.246M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 293294 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 378009 | 3 |
View Market Depth
| Last trade - 10.20am 27/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |